JP2024535851A5 - - Google Patents
Info
- Publication number
- JP2024535851A5 JP2024535851A5 JP2024516855A JP2024516855A JP2024535851A5 JP 2024535851 A5 JP2024535851 A5 JP 2024535851A5 JP 2024516855 A JP2024516855 A JP 2024516855A JP 2024516855 A JP2024516855 A JP 2024516855A JP 2024535851 A5 JP2024535851 A5 JP 2024535851A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021119011 | 2021-09-17 | ||
| CNPCT/CN2021/119011 | 2021-09-17 | ||
| PCT/CN2022/119334 WO2023041041A1 (en) | 2021-09-17 | 2022-09-16 | D3-binding molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535851A JP2024535851A (ja) | 2024-10-02 |
| JP2024535851A5 true JP2024535851A5 (https=) | 2025-10-01 |
Family
ID=85602107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516855A Pending JP2024535851A (ja) | 2021-09-17 | 2022-09-16 | Ｄ３結合分子及びその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240376194A1 (https=) |
| EP (1) | EP4401775A4 (https=) |
| JP (1) | JP2024535851A (https=) |
| KR (1) | KR20240055852A (https=) |
| CN (2) | CN118234510A (https=) |
| AU (1) | AU2022345323A1 (https=) |
| CA (1) | CA3231586A1 (https=) |
| CL (2) | CL2024000785A1 (https=) |
| CO (1) | CO2024003144A2 (https=) |
| CR (1) | CR20240135A (https=) |
| DO (1) | DOP2024000052A (https=) |
| EC (1) | ECSP24021498A (https=) |
| IL (1) | IL311510A (https=) |
| MX (1) | MX2024003331A (https=) |
| PE (1) | PE20241133A1 (https=) |
| WO (1) | WO2023041041A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121494919A (zh) * | 2024-12-16 | 2026-02-10 | 渤海大学 | 一种海参卵源肽复合物及其在抗氧化和降低黑色素上的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2530091T3 (en) * | 2010-01-29 | 2018-05-28 | Chugai Pharmaceutical Co Ltd | ANTI-DLL3 ANTIBODY |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| KR20160047567A (ko) * | 2013-08-28 | 2016-05-02 | 스템센트알엑스 인코포레이티드 | 조작된 항-dll3 접합체 및 사용 방법 |
| CA2939941A1 (en) * | 2014-02-21 | 2015-08-27 | Abbvie Stemcentrx Llc | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| MX2018002166A (es) * | 2015-08-20 | 2018-09-12 | Abbvie Stemcentrx Llc | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. |
| US20190225685A1 (en) * | 2018-01-24 | 2019-07-25 | Abbvie Stemcentrx Llc | Anti-dll3 antibody drug conjugates and methods of use |
| CA3097193A1 (en) * | 2018-05-08 | 2019-11-14 | Phanes Therapeutics, Inc. | Anti-dll3 antibodies and uses thereof |
| US10815311B2 (en) * | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| JP7611820B2 (ja) * | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
-
2022
- 2022-09-16 CN CN202280072803.0A patent/CN118234510A/zh active Pending
- 2022-09-16 MX MX2024003331A patent/MX2024003331A/es unknown
- 2022-09-16 CR CR20240135A patent/CR20240135A/es unknown
- 2022-09-16 CN CN202411637479.XA patent/CN119462942A/zh active Pending
- 2022-09-16 KR KR1020247012198A patent/KR20240055852A/ko active Pending
- 2022-09-16 CA CA3231586A patent/CA3231586A1/en active Pending
- 2022-09-16 PE PE2024000473A patent/PE20241133A1/es unknown
- 2022-09-16 IL IL311510A patent/IL311510A/en unknown
- 2022-09-16 EP EP22869407.1A patent/EP4401775A4/en active Pending
- 2022-09-16 AU AU2022345323A patent/AU2022345323A1/en active Pending
- 2022-09-16 WO PCT/CN2022/119334 patent/WO2023041041A1/en not_active Ceased
- 2022-09-16 JP JP2024516855A patent/JP2024535851A/ja active Pending
- 2022-09-16 US US18/692,311 patent/US20240376194A1/en active Pending
-
2024
- 2024-03-15 CO CONC2024/0003144A patent/CO2024003144A2/es unknown
- 2024-03-15 DO DO2024000052A patent/DOP2024000052A/es unknown
- 2024-03-15 CL CL2024000785A patent/CL2024000785A1/es unknown
- 2024-03-18 EC ECSENADI202421498A patent/ECSP24021498A/es unknown
-
2025
- 2025-02-11 CL CL2025000397A patent/CL2025000397A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7840836B2 (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP6728053B2 (ja) | 抗ｍｃａｍ抗体及び関連する使用方法 | |
| CN110669135B (zh) | 一种双特异性抗体及其用途 | |
| TW201837174A (zh) | 抗ｇｐｒｃ５ｄ抗體及包含該抗體之分子 | |
| JP2018532401A (ja) | 新規抗‐メソテリン抗体およびそれを含む組成物 | |
| KR20160131061A (ko) | 항-mcam 항체 및 관련된 사용 방법 | |
| JP7458567B2 (ja) | Ｃ－ｍｅｔ結合剤 | |
| JP2021512159A5 (https=) | ||
| JP2021534735A (ja) | ヒトＴｉｍ−３に対するモノクローナル抗体 | |
| KR102500845B1 (ko) | 항-tigit 항체 및 이의 용도 | |
| JP2023504733A (ja) | 抗ｃｌｅｃ－１ａ抗体及びその抗原結合性断片 | |
| JP2024535851A5 (https=) | ||
| JP2021501583A (ja) | 抗体および使用方法 | |
| WO2022126416A1 (zh) | 抗bcma抗体及其制备方法和应用 | |
| CN108290942A (zh) | 与人及小鼠信号素3a交联的抗体及其用途 | |
| WO2023093899A1 (zh) | 经修饰的蛋白或多肽 | |
| KR20230162597A (ko) | 안정적인 다중 특이성 분자 및 그 이용 | |
| CN116333128B (zh) | 靶向人lilrb2的纳米抗体及其应用 | |
| EP4393946A1 (en) | Cdc platform antibody | |
| JP2025541365A (ja) | 多価造血細胞係合因子または活性化因子 | |
| US20240425575A1 (en) | Anti-ang2 antibody, preparation method therefor, and application thereof | |
| JP2024533485A (ja) | がんの治療のためのＤＲ５標的化Ｍｕｌｔａｂｏｄｙ | |
| TW202544031A (zh) | 抗tigit/抗pd-l1雙特異性抗體及其用途 | |
| JP2025530261A (ja) | マルタボディを使用する化学療法耐性腫瘍の処置 | |
| CN118488971A (zh) | 优化的Multabody构建体、组合物和方法 |